LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 2 | M01 | 72 | hr | 1235 | 98 | 4513 | 0.0217 | -0.3472 |
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 3 | M01 | 72 | hr | 1235 | 392 | 4513 | 0.0868 | -0.2575 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 1 | O07 | 72 | hr | 1235 | 425 | 4513 | 0.0942 | -0.2474 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 2 | O07 | 72 | hr | 1235 | 460 | 4513 | 0.1019 | -0.2367 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 3 | O07 | 72 | hr | 1235 | 377 | 4513 | 0.0835 | -0.2621 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 1 | J19 | 72 | hr | 1235 | 549 | 4513 | 0.1216 | -0.2096 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 2 | J19 | 72 | hr | 1235 | 509 | 4513 | 0.1128 | -0.2218 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 3 | J19 | 72 | hr | 1235 | 599 | 4513 | 0.1327 | -0.1943 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 1 | M07 | 72 | hr | 1235 | 615 | 4513 | 0.1363 | -0.1895 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 2 | M07 | 72 | hr | 1235 | 709 | 4513 | 0.1571 | -0.1608 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 3 | M07 | 72 | hr | 1235 | 775 | 4513 | 0.1717 | -0.1406 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 1 | P13 | 72 | hr | 1235 | 3045 | 4513 | 0.6746 | 0.5519 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 2 | P13 | 72 | hr | 1235 | 2910 | 4513 | 0.6447 | 0.5107 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 3 | P13 | 72 | hr | 1235 | 3287 | 4513 | 0.7282 | 0.6258 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 1 | H01 | 72 | hr | 1235 | 506 | 4513 | 0.1121 | -0.2227 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 2 | H01 | 72 | hr | 1235 | 390 | 4513 | 0.0864 | -0.2581 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 3 | H01 | 72 | hr | 1235 | 624 | 4513 | 0.1383 | -0.1867 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 1 | L19 | 72 | hr | 1235 | 559 | 4513 | 0.1239 | -0.2065 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 2 | L19 | 72 | hr | 1235 | 638 | 4513 | 0.1414 | -0.1824 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 3 | L19 | 72 | hr | 1235 | 793 | 4513 | 0.1757 | -0.1351 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 1 | H07 | 72 | hr | 1235 | 620 | 4513 | 0.1374 | -0.1879 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 2 | H07 | 72 | hr | 1235 | 560 | 4513 | 0.1241 | -0.2062 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 3 | H07 | 72 | hr | 1235 | 727 | 4513 | 0.1611 | -0.1553 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 1 | G07 | 72 | hr | 1235 | 191 | 4513 | 0.0423 | -0.3188 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 2 | G07 | 72 | hr | 1235 | 255 | 4513 | 0.0565 | -0.2993 |